Non-epithelial ovarian cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 23, Issue SUPPL. 7, 2012, Pages

  Colombo, N ^a,d   Peiretti, M ^a   Garbi, A ^a   Carinelli, S ^a,c   Marini, C ^d   Sessa, C ^b,c  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c SAN RAFFAELE HOSPITAL   (Italy)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; BEVACIZUMAB; BLEOMYCIN; CALRETININ; CARBOPLATIN; CELL PROTEIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ETOPOSIDE; FOXL2 PROTEIN; GEMCITABINE; GESTAGEN; IFOSFAMIDE; INHIBIN; PACLITAXEL; PLATINUM COMPLEX; TAMOXIFEN; UNCLASSIFIED DRUG; VINBLASTINE; VINCRISTINE;

ADVANCED CANCER; ARTICLE; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CYTOREDUCTIVE SURGERY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG CHOICE; DRUG RESPONSE; DYSGERMINOMA; EARLY DIAGNOSIS; FOLLOW UP; HUMAN; METASTASIS; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; NONEPITHELIAL OVARIAN CANCER; OVARY CANCER; OVARY TUMOR; PRACTICE GUIDELINE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; SEX CORD TUMOR; TREATMENT DURATION; TREATMENT PLANNING;

EID: 84866603580     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds223     Document Type: Article

References (27)

1. Smith HO, Berwick M, Verschraegen CF et al. Incidence and survival rates for female malignant germ cell tumors. Obstet Gynecol 2006; 107(5): 1075-1085.
2. Parkinson CA, Hatcher HM, Ajithkumar TV. Management of malignant ovarian germ cell tumors. Obstet Gynecol Surv 2011; 66(8): 507-514.
3. Hildebrandt RH, Rouse RV, Longacre TA. Value of inhibin in the identification of granulosa cell tumors of the ovary. Hum Pathol 1997; 28: 1387-1395.
4. Colombo N, Parma G, Zanagnolo V et al. Management of ovarian stromal cell tumors. J Clin Oncol 2007; 25: 2944-2951.
5. Tavassoli FA, Deville P. Pathology and Genetics of Tumours of the Breast and Female genital organs. Lyon, France: International Agency for Research on Cancer 2003; 163-179.
6. Schumer S, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol 2003; 21(6): 1180-1189.
7. Al-Agha OM, Huwait HF, Chow C et al. FOXL2 is a sensitive and specific marker for sex cord-stromal tumors of the ovary. Am J Surg Pathol 2011; 35: 484-494.
8. Gopalan A, Dhall D, Olgac S et al. Testicular mixed germ cell tumors: a morphological and immunohistochemical study using stem cell markers, OCT3/4, SOX2 and GDF3, with emphasis on morphologically difficult-to-classify areas. Mod Pathol 2009; 22: 1066-1074.
9. Mahdi H, Swensen RE, Hanna R. Prognostic impact of lymphadenectomy in clinically early stage malignant germ cell tumour of the ovary. Br J Cancer 2011; 105(4): 493.
10. Brown J, Sood AK, Deavers MT et al. Patterns of metastasis in sex cord-stromal tumors of the ovary: Can routine staging lymphadenectomy be omitted? Gynecol Oncol 2009; 113(1): 86-90.
11. Chan JK, Zhang M, Kaleb V et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary-a multivariate analysis. Gynecol Oncol 2005; 96: 204-209.
12. Zhang M, Cheung MK, Shin JY et al. Prognostic factors responsible for survival in sex cord stromal tumors of the ovary: an analysis of 376 women. Gynecol Oncol 2007; 104(2): 396-400.
13. Mangili G, Scarfone G, Gadducci A et al. Is adjuvant chemotherapy indicated in stage I pure immature ovarian teratoma (IT)? A multicentre Italian trial in ovarian cancer (MITO-9). Gynecol Oncol 2010; 119(1): 48-52.
14. Gershenson DM. Management of early ovarian cancer: germ cell and sex cordstromal tumors. Gynecol Oncol 1994; 55(3 Pt 2): S62-S72.
15. Dark GG, Bower M, Newlands ES et al. Surveillance policy for stage I ovarian germ cell tumors. J Clin Oncol 1997; 15(2): 620-624.
16. Williams SD, Blessing JA, Hatch KD et al. Chemotherapy of advanced dysgerminoma: trials of the Gynecologic Oncology Group. J Clin Oncol 1991; 9: 1950-1955.
17. Bajorin DF, Sarosdy MF, Pfister GD et al. Randomized trial of etoposide and cisplatin versus etoposide and carboplatin in patients with good-risk germ cell tumors: a multi-institutional study. J Clin Oncol 1993;11: 598-606.
18. Manchana T, Ittiwut C, Mutirangura A et al. Targeted therapies for rare gynaecological cancers. Lancet Oncol 2010; 11(7): 685-693.
19. Homesley HD, Bundy BN, Hurteau JA et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 1999; 72: 131-137.
20. Obata NH, Nakashima N, Kawai M et al. Gonadoblastoma with dysgerminoma in one ovary and gonadoblastoma with dysgerminoma and yolk sac tumor in the contralateral ovary in a girl with 46XX karyotype. Gynecol Oncol 1995; 58: 124-128.
21. Wolf JK, Brown J. Management of stromal tumors of the ovary. ASCO 2008; 2008 Educational Book.
22. Pautier P, Gutierrez-Bonnaire M, Rey A et al. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors. Int J Gynecol Cancer 2008; 18: 446-452.
23. Teoh D, Freedman R, Soliman PT. Nearly 30 years of treatment for recurrent granulosa cell tumor of the ovary: a case report and review of the literature. Case Rep Oncol 2010; 3: 14-18.
24. Brown J, Shvartsman HS, Deavers MT et al. The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 2004; 22: 3517.
25. Evans AT, Gaffey TA, Malkasian GD et al. Clinicopathologic review of 118 granulosa and 82 theca cells tumors. Obstet Gynecol 1980; 55: 231.
26. Hardy RD, Bell JG, Nicely CJ et al. Hormonal treatment of a recurrent granulosa cell tumor of the ovary: case report and review of the literature. Gynecol Oncol 2005; 96: 865.
27. Tao X, Sood AK, Deavers MT et al. Anti-angiogenesis therapy with bevacizumab for patients with ovarian granulosa cell tumors. Gynecol Oncol 2009; 114: 431-436.